
Noscendo Closes Series A Funding Round
The company develops bioinformatics solutions to identify and assess pathogens in bloodstream-associated and related infections.
By
CIO Applications Europe | Wednesday, June 10, 2020

The company develops bioinformatics solutions to identify and assess pathogens in bloodstream-associated and related infections
Fremont, CA: Diagnostic firm Noscendo closed Series A round of financing of an undisclosed amount. The investment round was backed by new investors Earlybird, Paua Ventures, and the JIH Family Office and existing investors Wieland Capital and High-Tech Gründerfonds. The company will use the proceeds from the latest round of funding for further business expansion and product launch. "We are very excited about this financing round with the addition of such well-known investors and strong support from our current investors. We clearly see this as confirmation of the execution of our strategy and as a strong signal to enter into the next phase for our company," said Dr. Philip Stevens, Managing Director of Noscendo.
Noscendo is led by Dr. Philip Stevens (CEO), Dr. Peter Haug (CFO & Head of BD&L), Dr. Silke Grumaz, CSO, and Dr. Marcus Benz, COO. The company develops bioinformatics solutions to identify and assess pathogens in bloodstream-associated and related infections. The proprietary diagnostic platform, which enables the reliable detection of more than 1,500 bacteria, DNA viruses, fungi, and parasites in the patient's bloodstream based on cell-free DNA (cfDNA), has been validated together with German clinicians.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Dr. Grumaz and Dr. Benz are vital additions for the launch of DISQVER® into the European market, which is accompanied by the start of operations of Noscendo’s own testing and development lab. The product launch follows the successful pilot of the DISQVER® platform in 2019 in 8 maximum-care clinics throughout Germany. In addition to the launch of DISQVER®, the company will establish a Strategic and Scientific Advisory Boards consisting of world-class experts covering a variety of different research, development, and regulatory as well as marketing aspects.
“With DISQVER®, Noscendo addresses a significant gap in the rapid, reliable, and hypothesis-free diagnosis of infectious diseases, such as sepsis, a leading cause of death in the Western world. Noscendo will enable clinicians to deliver far better patient care, reducing patient mortality and severe side effects, and will reduce healthcare costs at the same time. We are very excited to support Noscendo in exploiting the full potential of its platform”, commented Rainer Christine, Partner at Earlybird, on behalf of all investors of this financing round.
Check out: Top Bioinformatics Solution Companies
More in News
Weekly Brief
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from CIO Applications Europe
THANK YOU FOR SUBSCRIBING


